Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

PD-1x VEGF bispecific antibody

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

PD-1x VEGF bispecific antibody

PF-08634404 | PF'4404 is an investigational compound.  Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

Rationale for Anti-PD-1 and anti-VEGF Combination

Bispecific antibodies that bind both VEGF and PD-(L)1 within the same molecule are being investigated as a therapeutic strategy distinct from single-agent targeted approaches1,2

 

Overview3,5

  • PF‑08634404 is an investigational bispecific antibody targeting PD‑1 and VEGF, featuring a tetravalent structure in which each arm can engage both targets
  • Preclinical studies have characterized PD‑1 binding interactions, including assessments of cooperative binding
  • In the presence of VEGF, PF‑08634404 has been observed to form multimers, that facilitate PD-1 binding interactions
  • PF-08634404 has a VEGF Fab arm designed to interact with vasculature and modulate VEGF-related immune pathways
  • PF‑08634404 is built on an IgG4 backbone, a format used in approved PD‑1–directed antibodies

 

 

Stage of Development

Lung

Non-Small and Small Cell Lung Cancer

Phase 1B/2 Combination

Phase 2 Monotherapy and Combination*

Phase 2/3 Combination

Phase 3 Combination
GI

Colorectal Cancer and Hepatocellular Carcinoma

Phase 1/2 Monotherapy and Combination

Phase 3 Combination
GU

Renal Cell Carcinoma

Phase 1B/2 Monotherapy and Combination
GI

Gastroesophageal Cancer

Phase 2/3 Combination
GU

Metastatic Urothelial Cancer

Phase 1B/2 Monotherapy and Combination
This information is current as of May 5th 2026.

*NCT07475287 is recruiting; NCT 07489066 is Not Yet Recruiting

MOA=mechanism of action; PD-1, programmed cell death protein 1; PDL-1=programmed death-ligand 1; VEGF, vascular endothelial growth factor.

 

REFERENCES:  1. Zhao et al. eClinicalMedicine. 2023;62:102106;  2. Xiong A, et al. Lancet. 2025;405(10481):839-849;  3. Xu et al. ESMO Annual Meeting. Presentation 796P; 4. Rispens et al., J Am Chem Soc. 2011;133:1032-11; 5. Lin et al. SITC 2025. Abstract 1328; 6. Clinicaltrials.gov.  https://clinicaltrials.gov/study/NCT07227298  Updated April 20, 2026; https://clinicaltrials.gov/study/NCT07489066 Updated March 23, 2026; https://clinicaltrials.gov/study/NCT07226999  Updated April 20, 2026; https://clinicaltrials.gov/study/NCT07222566  Updated April 20, 2026; https://clinicaltrials.gov/study/NCT07227012  Updated April 20, 2026; https://clinicaltrials.gov/study/NCT07392892  Updated April 13, 2026; https://clinicaltrials.gov/study/NCT07222800 Updated April 21, 2026; https://clinicaltrials.gov/study/NCT07227415 Updated April 20, 2026. https://clinicaltrials.gov/study/NCT07421700 Updated April 20, 2026. Accessed April 21, 2026.